指南与共识冠心病外科瓣膜外科心外重症与机械循环支持

共识声明:心脏外科与机械支持中的止血试验结局

Consensus Statement: Hemostasis Trial Outcomes in Cardiac Surgery and Mechanical Support.
指南 / 共识 · Ann Thorac Surg · 2021-11-24

美国国家心肺血液研究所与美国国防部召集的专家组制定共识,针对心脏外科与机械循环支持的止血试验主要结局提出推荐:心脏外科推荐术后至第5天或出院的总异体血制品输注量(单位或儿童mL/kg)为主要疗效终点;体外膜氧合推荐5点序数评分;心室辅助装置推荐180天内无致残性卒中。

要点

  • 心脏外科止血试验主要疗效终点推荐为术中及术后至第5天或出院的总异体血制品输注量(单位,儿童用mL/kg)。
  • 体外膜氧合非围术期主要结局推荐采用改编自常见不良事件评价标准5.0版的5点血栓与出血严重程度序数评分。
  • 心室辅助装置主要终点推荐为180天内无致残性卒中(常见不良事件评价标准≥3级)。

核心结论

  • 提出的复合风险评分可影响未来临床试验设计并使研究间具有可比性。
  • 统一并传播全球共识定义与管理指南可减少患者异质性,避免混杂未来研究中的标准化主要结局。

研究设计与样本

  • 由美国国家心肺血液研究所与美国国防部召集的专家组制定共识推荐。

主要发现

  • 心脏外科推荐术中及术后至第5天或出院的总异体血制品输注量(单位;儿童用mL/kg)作为主要疗效终点。
  • 体外膜氧合非围术期推荐采用改编自常见不良事件评价标准5.0版的5点血栓与出血严重程度序数评分作为主要结局。
  • 心室辅助装置推荐180天内无致残性卒中(常见不良事件评价标准≥3级)作为主要终点。

关键数值与推荐

  • 心脏外科主要疗效终点:术中及术后至第5天或出院的总异体血制品输注量(单位;儿童用mL/kg)。
  • 体外膜氧合非围术期主要结局:改编自常见不良事件评价标准5.0版的5点血栓与出血严重程度序数评分。
  • 心室辅助装置主要终点:180天内无致残性卒中(常见不良事件评价标准≥3级)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Research evaluating hemostatic agents for the treatment of clinically significant bleeding has been hampered by inconsistency and lack of standardized primary clinical trial outcomes. Clinical trials of hemostatic agents in both cardiac surgery and mechanical circulatory support, such as extracorporeal membrane oxygenation and ventricular assist devices, are examples of studies that lack implementation of universally accepted outcomes. METHODS: A subgroup of experts convened by the National Heart, Lung, and Blood Institute and the US Department of Defense developed consensus recommendations for primary outcomes in cardiac surgery and mechanical circulatory support. RESULTS: For cardiac surgery the primary efficacy endpoint of total allogeneic blood products (units vs mL/kg for pediatric patients) administered intraoperatively and postoperatively through day 5 or hospital discharge is recommended. For mechanical circulatory support outside the perioperative period the recommended primary outcome for extracorporeal membrane oxygenation is a 5-point ordinal score of thrombosis and bleeding severity adapted from the Common Terminology Criteria for Adverse Events version 5.0. The recommended primary endpoint for ventricular assist device is freedom from disabling stroke (Common Terminology Criteria for Adverse Events AE ≥ grade 3) through day 180. CONCLUSIONS: The proposed composite risk scores could impact the design of upcoming clinical trials and enable comparability of future investigations. Harmonizing and disseminating global consensus definitions and management guidelines can also reduce patient heterogeneity that would confound standardized primary outcomes in future research.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Levy JH, Faraoni D, Almond CS, et al. Consensus Statement: Hemostasis Trial Outcomes in Cardiac Surgery and Mechanical Support. Ann Thorac Surg. 2021. PMID: 34826386. doi:10.1016/j.athoracsur.2021.09.080

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。